Compare ALNT & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALNT | KALV |
|---|---|---|
| Founded | 1962 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | 1995 | 2014 |
| Metric | ALNT | KALV |
|---|---|---|
| Price | $65.96 | $26.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $64.50 | $32.60 |
| AVG Volume (30 Days) | 157.9K | ★ 4.1M |
| Earning Date | 05-06-2026 | 07-09-2026 |
| Dividend Yield | ★ 0.16% | N/A |
| EPS Growth | ★ 67.09 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $554,478,000.00 | $50,000,000.00 |
| Revenue This Year | $7.53 | $185.42 |
| Revenue Next Year | $6.64 | $59.23 |
| P/E Ratio | $206.75 | ★ N/A |
| Revenue Growth | 4.62 | ★ 495.66 |
| 52 Week Low | $29.25 | $9.83 |
| 52 Week High | $80.39 | $26.85 |
| Indicator | ALNT | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 41.29 | 75.30 |
| Support Level | $57.71 | $14.66 |
| Resistance Level | $67.79 | N/A |
| Average True Range (ATR) | 3.65 | 0.57 |
| MACD | -1.04 | 0.45 |
| Stochastic Oscillator | 26.29 | 98.47 |
Allient Inc, formerly Allied Motion Technologies Inc designs, manufactures, and sells precision and specialty controlled motion components and systems. The firm mainly caters to the Industrial, Vehicle, Aerospace & Defense, and Medical sectors. It mainly operates and sells across the United States, Canada, South America, Europe, and Asia. Its products and solutions include nano precision positioning systems, servo control systems, motion controllers, digital servo amplifiers and drives, brushless servo, torque, and coreless motors, brush motors, integrated motor drives, gear motors, gearing, incremental and absolute optical encoders, active (electronic) and passive (magnetic) filters for power quality and harmonic issues.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.